氯雷他定在小儿咳嗽变异性哮喘治疗中的应用研究

Study on application of Loratadine for treatment of infantile cough variant asthma

目的:观察氯雷他定在治疗小儿咳嗽变异性哮喘的临床效果及不良反应。方法:选取该院儿科病区的90例咳嗽变异性哮喘患儿,随机分为对照组和试验组,每组45例,对照组采用常规治疗方法治疗,试验组给予常规治疗和氯雷他定治疗,分析比较2组患儿的治疗效果及复发情况。结果:试验组总有效例数有42例,占93.33%;对照组总有效例数有35例,占77.78%(χ2=4.4,P<0.05﹚;6个月后随访,试验组有10例复发,对照组有20例复发(χ2=5,P<0.05﹚。试验组及对照组的临床症状缓解时间分别为(4.98±1.56)天、(6.45±1.34)天(t=4.795,P<0.05)。结论:氯雷他定对小儿咳嗽变异性哮喘的治疗效果较好,能较早缓解临床症状,提高患者的生活质量。

Objective： To observe the clinical effect and adverse reactions of Loratadine for treatment of infantile cough variant asthma. Methods： A total of 90 infants with cough variant asthma were selected from pediatric department in the hospital, then they were divided into control group and experimental group, 45 infants in each group; the infants in control group were treated with routine therapy, while the infants in experimental group were treated with routine therapy and Loratadine; the curative effects and recurrence situations in the two groups were analyzed and compared. Results： The total effective rates in experimental group and control group were 93.33% （42 infants） and 77. 78% （35 infants）, respectively, there was statistically significant difference between the two groups （χ2 =4.4, P 〈0. 05） ; all the infants in the two groups were followed up at six months after treatment, cough variant asthma occurred in 10 infants in experimental group and 20 infants in control group, there was statistically significant difference between the two groups （χ2 = 5, P 〈 0. 05 ） . The remission times of clinical symptoms in experimental group and control group were （4. 98 ±1.56 ） days and （ 6.45 ± 1.34 ） days, respectively, there was statistically significant difference between the two groups （ t = 4. 795, P 〈 0. 05 ） . Conclusion： The curative effect of Loratadine for treatment of infantile cough variant asthma was good, which can relieve clinical symptoms early and improve the quality of life of the patients.